Ultragenyx Pharmaceutical Inc. (RARE) — Financial statements
Income statement, balance sheet, and cash flow for Ultragenyx Pharmaceutical Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 673↑20.1% | 560↑29.0% | 434↑19.5% | 363↑3.4% | 351 | |
| Cost of Revenue | 109↑42.1% | 77↑69.7% | 45↑59.6% | 28↑76.9% | 16 | |
| Gross Profit | 564↑16.6% | 484↑24.3% | 389↑16.1% | 335↓0.1% | 335 | |
| Operating Expenses | ||||||
| R&D Expenses | 750↑7.5% | 698↑7.6% | 648↓8.1% | 706↑42.0% | 497 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 349↑8.5% | 322↑3.8% | 310↑11.4% | 278↑26.4% | 220 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 1,099↑7.8% | 1,019↑6.4% | 958↓2.6% | 984↑37.2% | 717 | |
| Total Costs & Expenses | 1,208↑10.2% | 1,096↑9.2% | 1,003↓0.9% | 1,012↑38.1% | 733 | |
| Operating Results | ||||||
| Operating Income | -535↑0.2% | -536↑5.8% | -569↑12.3% | -649↓70.0% | -382 | |
| Depreciation & Amortization | 35↓1.5% | 36↑36.7% | 26↑42.7% | 18↑37.6% | 13 | |
| EBITDA | -500↓6.6% | -469↑9.2% | -516↑19.4% | -640↓56.1% | -410 | |
| EBIT | -535↓6.0% | -505↑7.0% | -542↑17.6% | -659↓55.5% | -424 | |
| Interest & Other Income | ||||||
| Net Interest Income | -37↓39.4% | -27↑32.5% | -39↓23.1% | -32↓16.2% | -27 | |
| Interest Income | 25↓31.5% | 37↑36.8% | 27↑141.0% | 11↑474.4% | 2 | |
| Interest Expense | 62↓1.7% | 63↓4.5% | 66↑53.4% | 43↑46.2% | 29 | |
| Non-Operating Income | 0.00↑100.0% | -31↓17.5% | -27↓373.2% | 10↓76.6% | 42 | |
| Other Income / Expenses | -36↓13.9% | -32↑19.5% | -39↑25.7% | -53↑25.9% | -71 | |
| Income Before Tax | -571↓0.6% | -568↑6.7% | -608↑13.3% | -702↓54.9% | -453 | |
| Income Tax Expense | 4↑150.5% | 2↑187.5% | -2↓132.0% | 6↑445.6% | 1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -575↓1.0% | -569↑6.2% | -607↑14.2% | -707↓55.8% | -454 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -575↓1.0% | -569↑6.2% | -607↑14.2% | -707↓55.8% | -454 | |
| Bottom-Line Net Income | -575↓1.0% | -569↑6.2% | -607↑14.2% | -707↓55.8% | -454 | |
| EPS (Basic) | -5.83↑7.3% | -6.29↑23.8% | -8.25↑18.5% | -10.12↓51.0% | -6.70 | |
| EPS (Diluted) | -5.83↑7.3% | -6.29↑23.8% | -8.25↑18.5% | -10.12↓51.0% | -6.70 | |
| Weighted Average Shares | 99↑8.9% | 91↑23.1% | 74↑5.2% | 70↑3.1% | 68 | |
| Weighted Average Diluted Shares | 99↑8.9% | 91↑23.1% | 74↑5.2% | 70↑3.1% | 68 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.